Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Cancer Institute (NCI)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Novartis
National Cancer Institute (NCI)
Kivu Bioscience Inc.
National Cancer Institute, Egypt
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BioNTech SE
M.D. Anderson Cancer Center
Genentech, Inc.
AstraZeneca
Hummingbird Bioscience
Boehringer Ingelheim
Yale University
University of Cincinnati
Fox Chase Cancer Center
University of Texas Southwestern Medical Center
Groupe Oncologie Radiotherapie Tete et Cou
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Bristol-Myers Squibb
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Providence Health & Services
University of California, San Francisco
Eli Lilly and Company
Janssen Research & Development, LLC
Medical University of South Carolina
National Cancer Institute (NCI)
Johnson & Johnson Enterprise Innovation Inc.
Janssen Research & Development, LLC
University of Pittsburgh
Royal Marsden NHS Foundation Trust
The Methodist Hospital Research Institute
Providence Health & Services
University of Chicago
OncoC4, Inc.
GlaxoSmithKline
AVEO Pharmaceuticals, Inc.
Washington University School of Medicine
Genmab
IO Biotech
University of Arkansas